factual

England's NICE uses cost-effectiveness thresholds

England's NICE panel evaluates each treatment using a cost-effectiveness ratio of about £30,000 per life-year; drugs priced above that threshold are often repriced downward by manufacturers to qualify, and treatments deemed not sufficiently cost-effective are not paid for by the NHS, which is tremendously controversial when a drug just misses the threshold.

factualpending

Speaker

Jonathan Skinner

Evidence Quote

“if the treatment is not sufficiently cost-effective, they will often say, 'No, we're not going to provide this. We are not going to pay for this.'”

Source

Jonathan Skinner on Health Care Costs, Technology, and Rising Mortality— EconTalk
Created: 6/13/2026, 12:21:47 AM

Your notes

Loading notes...